Form 4: Surrozen CEO Craig C. Parker Reports Stock Option and Restricted Stock Unit Awards

Craig C. Parker, CEO of Surrozen, Inc., reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC Form 4 filing.

Summary

• On May 1, 2025, Craig C. Parker, the CEO of Surrozen, Inc., was granted stock options to purchase 75,000 shares of common stock at an exercise price of $10.48.
• These options vest in 48 equal monthly installments starting from the grant date, contingent upon Parker's continued service.
• Parker also received 25,000 restricted stock units (RSUs), each representing a contingent right to receive one share of Surrozen's common stock.
• The RSUs vest over a two-year period, with 50% vesting on each of the first and second annual anniversary of the grant date, also subject to continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity compensation is a standard practice and suggests confidence in the CEO's continued leadership. There are no explicitly negative indicators.

Positives

• The grant of stock options and RSUs to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedules encourage long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service and contribution from the CEO.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain top talent and align their interests with those of shareholders. The vesting schedules are typical for such grants.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard compensation tools for CEOs in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead, and Biogen also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules (4-year monthly for options, 2-year annual for RSUs) are within the typical range observed in the industry.

Stakeholder Impact

• Shareholders: The equity grants align the CEO's interests with increasing shareholder value.
• Employees: The grants may have a positive impact on employee morale by demonstrating the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Surrozen, SRZN, Stock Options, Restricted Stock Units, CEO, Craig C. Parker, Beneficial Ownership